Goserelin

Gonadotropin Releasing Hormone Receptor Agonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Goserelin is a drug in the Gonadotropin Releasing Hormone Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1989. Its mechanism of action is classified as Gonadotropin Releasing Hormone Receptor Agonists. DrugCentral lists 2 molecular targets, including LHCGR and GNRHR. Recorded indications include Advanced Prostatic Carcinoma, Endometrial Ablation Adjunct, Endometriosis and Hormone receptor positive malignant neoplasm of breast.

• Drug class: Gonadotropin Releasing Hormone Receptor Agonist.
• Mechanism of action: Gonadotropin Releasing Hormone Receptor Agonists.
• Molecular targets: LHCGR and GNRHR (2 listed in DrugCentral).
• Indications: Advanced Prostatic Carcinoma, Endometrial Ablation Adjunct, Endometriosis and Hormone receptor positive malignant neoplasm of breast.
• ATC code: L02AE03 (Gonadotropin releasing hormone analogues).
• Molecular formula: C59H84N18O14; molecular weight 1269.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Advanced Prostatic Carcinoma
• Endometrial Ablation Adjunct
• Endometriosis
• Hormone receptor positive malignant neoplasm of breast

Contraindications (14)

• Bilateral orchidectomy
• Bone Metastases
• Breastfeeding (mother)
• Cardiovascular event risk
• Diabetes mellitus
• Hypercalcemia
• Hypercholesterolemia
• Hyperglycemia
• Hypertensive disorder
• Obesity
• Pregnancy, function
• Smokes tobacco daily
• Urinary tract obstruction
• Vertebral Metastases

Mechanism & targets

• Mechanism of action (MoA): Gonadotropin Releasing Hormone Receptor Agonists
• Established pharmacologic class: Gonadotropin Releasing Hormone Receptor Agonist

Molecular targets (2)

Target	Gene	Action	Activity
Lutropin-choriogonadotropic hormone receptor	LHCGR	unknown	—
Gonadotropin-releasing hormone receptor	GNRHR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1989-12-29	FDA	—	ASTRAZENECA

ATC classification

ATC code	Therapeutic hierarchy
L02AE03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONES AND RELATED AGENTS › Gonadotropin releasing hormone analogues

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: ESR1, ESR2, PGR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Malignant neoplasm progression	1781.4
Metastases to bone	1580.2
Metastases to liver	969.5
Neutropenia	497.0
Prostatic specific antigen increased	477.4
Hot flush	342.5
Metastases to lung	319.6
Osteonecrosis of jaw	310.2
Metastases to lymph nodes	305.0
Expulsion of medication	295.0
Breast cancer metastatic	240.1
PIK3CA-activated mutation	217.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Goserelin is on its molecule page.

• Molecular formula: C₅₉H₈₄N₁₈O₁₄
• Molecular weight: 1269.43 g/mol
• CAS number: 65807-02-5
• InChIKey: BLCLNMBMMGCOAS-URPVMXJPSA-N
• PubChem CID: 5311128

CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Goserelin used for?

DrugCentral lists the following indications for Goserelin: Advanced Prostatic Carcinoma, Endometrial Ablation Adjunct, Endometriosis and Hormone receptor positive malignant neoplasm of breast.

How does Goserelin work?

Goserelin is classified as Gonadotropin Releasing Hormone Receptor Agonists; its molecular targets in DrugCentral include LHCGR and GNRHR (agonist).

When was Goserelin first approved?

Goserelin was first approved by the FDA in 1989.

What drug class does Goserelin belong to?

Goserelin is in the Gonadotropin Releasing Hormone Receptor Agonist class.

What is the chemical formula of Goserelin?

Goserelin has the molecular formula C59H84N18O14 and a molecular weight of 1269.43 g/mol.

Sources

• DrugCentral drug card 1327 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200501 — compound record and bioactivity
• PubChem CID 5311128 — chemical identifiers
• DrugBank DB00014 — drug record
• FDA UNII 0F65R8P09N — substance identity
• DailyMed: FDA labels for Goserelin — current prescribing information (label search)
• UniProt P22888 (LHCGR) — target protein
• UniProt P30968 (GNRHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.